How are azathioprine and 6-mercaptopurine dosed by gastroenterologists? Results of a survey of clinical practice

Inflammatory Bowel Diseases

Volumn 14, Issue 4, 2008, Pages 514-518

  Yip, Jason S ^a   Woodward, Mark ^a   Abreu, Maria T ^a   Sparrow, Miles P ^b  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^b BOX HILL HOSPITAL   (Australia)

Author keywords

6 mercaptopurine; Azathioprine; Crohn's disease; Metabolite levels; Thiopurine methyltransferase; Ulcerative colitis

Indexed keywords

AZATHIOPRINE; INFLIXIMAB; MERCAPTOPURINE; MESALAZINE; THIOPURINE METHYLTRANSFERASE;

ARTICLE; CLINICAL PRACTICE; CONTROLLED STUDY; CROHN DISEASE; DRUG DOSE ESCALATION; DRUG DOSE REGIMEN; ENTERITIS; HEALTH SURVEY; HUMAN; MEDICAL SPECIALIST; PRACTICE GUIDELINE; PRESCRIPTION; PRIORITY JOURNAL; QUESTIONNAIRE; TREATMENT DURATION; TREATMENT INDICATION; ULCERATIVE COLITIS;

6-MERCAPTOPURINE; AZATHIOPRINE; COLITIS, ULCERATIVE; CROHN DISEASE; DATA COLLECTION; GASTROENTEROLOGY; HUMANS; IMMUNOSUPPRESSIVE AGENTS; PRACTICE GUIDELINES AS TOPIC;

EID: 42449134867     PISSN: 10780998     EISSN: 15364844     Source Type: Journal    
DOI: 10.1002/ibd.20345     Document Type: Article

References (22)

1. Lichtenstein GR, Abreu MT, Cohen R, et al. Gastroenterological Association Institute technical review on corticosteroids, immunomodulators. and infliximab in inflammatory bowel disease. Gastroenterology. 2006; 130:940-987.
2. Pearson DC, May GR, Fick GH, et al. Azathioprine for maintaining remission of Crohn's disease. Cochrane Database Syst Rev. 2000; CD000067.
3. Sandborn W, Sutherland L, Pearson D, et al. Azathioprine or 6-mercaptopurine for inducing remission of Crohn's disease. Cochrane Database Syst Rev. 2000;CD000545.
4. Kirk AP, Lennard-Jones JE. Controlled trial of azathioprine in chronic ulcerative colitis. Br Med J (Clin Res Ed). 1982;284:1291-1292.
5. Hawthorne AB, Logan RF, Hawkey CJ, et al. Randomized controlled trial of azathioprine withdrawal in ulcerative colitis. BMJ. 1992;305:20-22.
6. Ardizzone S, Maconi G, Russo A, et al. Randomised controlled trial of azathioprine and 5-aminosalicylic acid for treatment of steroid dependent ulcerative colitis. Gut. 2006;55:47-53.
7. Candy S, Wright J, Gerber M, et al. A controlled double blind study of azathioprine in the management of Crohn's disease. Gut. 1995;37:674-678.
8. Elion G. The comparative metabolism of Imuran and 6-mercaptopurine in man. Proc Am Assoc Cancer Res. 1969;10:21.
9. Markowitz J, Grancher K, Kohn N, et al. A multicenter trial of 6-mercaptopurine and prednisone in children with newly diagnosed Crohn's disease. Gastroenterology. 2000;119:895-902.
10. Sandborn WJ. A review of immune modifier therapy for inflammatory bowel disease: azathioprine, 6-mercaptopurine, cyclosporine, and methotrexate. Am J Gastroenterol. 1996;91:423-433.
11. Siegel CA, Sands BE. Review article: practical management of inflammatory bowel disease patients taking immunomodulators. Aliment Pharmacol Ther. 2005;22:1-16.
12. Gisbert JP, Nino P, Rodrigo L, et al. Thiopurine methyltransferase (TPMT) activity and adverse effects of azathioprine in inflammatory bowel disease: long-term follow-up study of 394 patients. Am J Gastroenterol. 2006;101:2769-2776.
13. Dubinsky MC, Lamothe S, Yang HY, et al. Pharmacogenomics and metabolite measurement for 6-mercaptopurine therapy in inflammatory bowel disease. Gastroenterology,. 2000;118:705-713.
14. Osterman MT, Kundu R, Lichtenstein GR, et al. Association of 6-thioguanine nucleotide levels and inflammatory bowel disease activity: a meta-analysis. Gastroenterology. 2006;130:1047-1053.
15. Hindorf U, Lindqvist M, Peterson C, et al. Pharmacogenetics during standardised initiation of thiopurine treatment in inflammatory bowel disease. Gut. 2006;55:1423-1431.
16. Reddy SI, Friedman S, Telford JJ, et al. Are patients with inflammatory bowel disease receiving optimal care? Am J Gastroenterol. 2005;100: 1357-1361.
17. Dubinsky MC, Reyes E, Ofman J, et al. A cost-effectiveness analysis of alternative disease management strategies in patients with Crohn's disease treated with azathioprine or 6-mercaptopurine. Am J Gastroenterol. 2005;100:2239-2247.
18. Dubinsky MC, Yang H, Hassard PV, et al. 6-MP metabolite profiles provide a biochemical explanation for 6-MP resistance in patients with inflammatory bowel disease. Gastroenterology. 2002;122:904-915.
19. Baert F, Noman M, Vermeire S, et al. Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease. N Engl J Med. 2003;348:601-608.
20. Mackey AC, Green L, Liang LC, et al. Hepatosplenic T cell lymphoma associated with infliximab use in young patients treated for inflammatory bowel disease. J Pediatr Gastroenterol Nutr. 2007;44:265-267.
21. Morales A, Salguti S, Miao CL, et al. Relationship between 6-mercaptopurine dose and 6-thioguanine nucleotide levels in patients with inflammatory bowel disease. Inflamm Bowel Dis. 2007;13:380-385.
22. Gisbert JP, Luna M, Maté J, et al. Choice of azathioprine or 6-mercaptopurine dose based on thiopurine methyltransferase (TPMT) activity to avoid myelosuppression. A prospective study. Hepatogastroenterology. 2006;53:399-404.